Loading data for GNLX — first visit, this takes a few seconds.
Genelux Corporation (GNLX) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$0.21 | -$0.01 | -5.00% |
Metrics
- Bid
- 1.76
- Market Cap
- 112M
- Net Income (ttm)
- -35.6M
- 0.56
- -0.84
- n/a
- -3.33
- P/B (ttm)
- 6.84
- P/S (ttm)
- 13969.50
- Earnings Date
- n/a
- Ask
- 3.08
- Volume
- 80,898
- Avg. Volume (20D)
- 270,001
- Open
- 2.53
- Previous Close
- 2.54
- Day's Range
- 2.40 - 2.53
- 52-Week Range
- 2.29 - 8.54
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Genelux Corporation
View profile →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2023
Employees 25
Stock Exchange NasdaqCM
Ticker Symbol GNLX
Website https://www.genelux.com